Nalaganje...

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

BACKGROUND: The optimal sequence of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Suzman, Daniel L., Luber, Brandon, Schweizer, Michael T., Nadal, Rosa, Antonarakis, Emmanuel S.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144818/
https://ncbi.nlm.nih.gov/pubmed/25053178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22844
Oznake: Označite
Brez oznak, prvi označite!